Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Core Phase up to 36 Months	STARTED	Imatinib First, Then Nilotinib	324
Core Phase up to 36 Months	STARTED	Nilotinib First, Then Imatinib	320
Core Phase up to 36 Months	COMPLETED	Imatinib First, Then Nilotinib	0
Core Phase up to 36 Months	COMPLETED	Nilotinib First, Then Imatinib	0
Core Phase up to 36 Months	NOT COMPLETED	Imatinib First, Then Nilotinib	324
Core Phase up to 36 Months	NOT COMPLETED	Nilotinib First, Then Imatinib	320
Optional Extension Phase	STARTED	Imatinib First, Then Nilotinib	39
Optional Extension Phase	STARTED	Nilotinib First, Then Imatinib	125
Optional Extension Phase	COMPLETED	Imatinib First, Then Nilotinib	0
Optional Extension Phase	COMPLETED	Nilotinib First, Then Imatinib	0
Optional Extension Phase	NOT COMPLETED	Imatinib First, Then Nilotinib	39
Optional Extension Phase	NOT COMPLETED	Nilotinib First, Then Imatinib	125

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00785785/flow